Development asset linked to Grünenthal in public FDA and regional records.
pharma · Moderate to severe pain associated with Osteoarthritis of the knee · Not applicable for phase I study
Grünenthal
Gruenenthal GmbH
Grünenthal drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Aachen, DE HQ
4,668 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Aachen, DE
- Employees
- 4,668
- Programs
- 3
- Drugs
- 5
- Patents
- 0
Grünenthal pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Grünenthal drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Grünenthal in public FDA and regional records.
-
Development asset linked to Grünenthal in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Grünenthal in public FDA and regional records.